ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
A
A
Tempescul
J C
JC
Ianotto
J R
JR
Eveillard
G
G
Guillerm
C
C
Berthou
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D000077269:Lenalidomide; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014182:Transplantation, Autologous
D003561:Cytarabine; D013792:Thalidomide; D005047:Etoposide; D000077269:Lenalidomide; D002945:Cisplatin; D011241:Prednisone